Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#113 of 458

Debjit Chattopadhyay

Guggenheim · Equity Research Analyst
ProvisionalRating since 2022No new ratings since Aug 2025

Analyst rating accuracy & track record

Debjit Chattopadhyay is an equity research analyst at Guggenheim. Quantellect has scored 23 of their stock calls across 13 companies. Their picks beat their sector 44% of the time over the next 12 months, and their price targets were reached 46% of the time within a year.

Win % vs sector
44%
PT Hit % (12mo)
46%
Avg sector-excess
+0.7%
Scored calls
23
Tickers
13
Tier
Provisional

Track record

Quantellect has scored 23 of Debjit Chattopadhyay's stock calls across 13 companies, dating back to 2022. Their rated stocks beat their own sector 44% of the time over the next 12 months. On a typical call, a Chattopadhyay pick returned +0.7% more than its sector over the following year.

Of the scored calls, 23 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
PASGPassage Bio Inc
Buy$10.00Aug 2025−58.4%Hit
PASGPassage Bio Inc
Buy$10.00Aug 2025−58.4%Hit
PRMEPrime Medicine, Inc. Common Stock
Buy$5.00Aug 2025−40.2%Hit
VRTXVertex Pharmaceuticals Inc
Buy$546.00Aug 2025−0.3%Miss
RAREUltragenyx
Buy$64.00Jun 2025−36.2%Miss
DYNDyne Therapeutics Inc
Buy$50.00Jun 2025+77.7%Miss
SLNOSoleno Therapeutics Inc
Buy$97.00May 2025−63.2%Miss
BEAMBeam Therapeutics Inc
Buy$55.00May 2025+72.6%Miss
MAZEMaze Therapeutics, Inc. Common Stock
Buy$19.00Apr 2025+203.6%Hit
SLNOSoleno Therapeutics Inc
Buy$81.00Mar 2025−71.7%Hit
CNTACentessa Pharmaceuticals PLC ADR
Buy$28.00Mar 2025+87.6%Hit
BEAMBeam Therapeutics Inc
Buy$78.00Feb 2025−1.4%Miss
MAZEMaze Therapeutics, Inc. Common Stock
Buy$19.00Feb 2025+295.0%Hit
RZLTRezolute Inc
BuyFeb 2025−44.0%
CNTACentessa Pharmaceuticals PLC ADR
BuyFeb 2025+20.8%
BNTCBenitec Biopharma Ltd ADR
Buy$17.00Dec 2024+20.1%Hit
CNTACentessa Pharmaceuticals PLC ADR
Buy$28.00Nov 2024+55.1%Miss
BNTCBenitec Biopharma Ltd ADR
Buy$17.00Sep 2024+80.0%Hit
RZLTRezolute Inc
Buy$11.00Aug 2024+64.8%Miss
DTILPrecision BioSciences Inc
Buy$19.00Apr 2024−47.7%Miss
VYGRVoyager Therapeutics Inc
Buy$22.00Mar 2024−61.5%Miss
SLNOSoleno Therapeutics Inc
Buy$40.00Nov 2023+64.3%Hit
PASGPassage Bio Inc
Buy$11.00Nov 2022−56.3%Miss
Prev1Next
Go to

Debjit Chattopadhyay: analyst track record FAQ

Is Debjit Chattopadhyay a good stock analyst?

Yes, by track record. Debjit Chattopadhyay ranks number 113 of 458 of the analysts Quantellect scores, with a Q Score of 52 out of 100. Past results do not guarantee future ones.

What is Debjit Chattopadhyay's win rate?

Debjit Chattopadhyay's win rate is 44%. Across 23 scored calls, their rated stocks beat their sector 44% of the time over the next 12 months. On a typical call they returned +0.7% more than the sector.

What stocks and sectors does Debjit Chattopadhyay cover?

Debjit Chattopadhyay covers 13 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Debjit Chattopadhyay's price targets accurate?

Debjit Chattopadhyay's price targets are reached within 12 months 46% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Debjit Chattopadhyay's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Debjit Chattopadhyay rank among Wall Street analysts?

Debjit Chattopadhyay ranks number 113 of 458 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.